TP53 and Barrett esophagus: In esophageal adenocarcinoma (EAC), significant mutations of TP53 (71%) and CDKN2A (14%) have been reported [100], and these results were consistent with the prominence of TP53 and CDKN2A mutations in Barrett’s esophagus, a precancerous condition of EAC.